122 related articles for article (PubMed ID: 20660102)
1. Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas.
Khier S; Gattacceca F; El Messaoudi S; Lafaille F; Deleuze-Masquéfa C; Bompart J; Cooper JF; Solassol I; Pinguet F; Bonnet PA; Bressolle FM
Drug Metab Dispos; 2010 Oct; 38(10):1836-47. PubMed ID: 20660102
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS.
Khier S; Moarbess G; Deleuze-Masquefa C; Solassol I; Margout D; Pinguet F; Bonnet PA; Bressolle FM
J Sep Sci; 2009 May; 32(9):1363-73. PubMed ID: 19399864
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry.
Lafaille F; Solassol I; Enjalbal C; Bertrand B; Doulain PE; Vappiani J; Bonnet PA; Deleuze-Masquéfa C; Bressolle FM
J Pharm Biomed Anal; 2014 Jan; 88():429-40. PubMed ID: 24176748
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice.
Chouchou A; Marion B; Enjalbal C; Roques C; Cuq P; Bonnet PA; Bressolle-Gomeni FMM; Deleuze-Masquéfa C
J Pharm Biomed Anal; 2018 Jan; 148():369-379. PubMed ID: 29111492
[TBL] [Abstract][Full Text] [Related]
5. Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.
Courbet A; Bec N; Constant C; Larroque C; Pugniere M; El Messaoudi S; Zghaib Z; Khier S; Deleuze-Masquefa C; Gattacceca F
PLoS One; 2017; 12(8):e0182022. PubMed ID: 28797090
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Khier S; Deleuze-Masquéfa C; Moarbess G; Gattacceca F; Margout D; Solassol I; Cooper JF; Pinguet F; Bonnet PA; Bressolle FM
Eur J Pharm Sci; 2010 Jan; 39(1-3):23-9. PubMed ID: 19854270
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
10. Disposition of remoxipride in different species. Species differences in metabolism.
Widman M; Nilsson LB; Bryske B; Lundström J
Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
[TBL] [Abstract][Full Text] [Related]
13. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
Mani C; Gelboin HV; Park SS; Pearce R; Parkinson A; Kupfer D
Drug Metab Dispos; 1993; 21(4):645-56. PubMed ID: 8104124
[TBL] [Abstract][Full Text] [Related]
15. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
[TBL] [Abstract][Full Text] [Related]
18. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes.
Quintieri L; Fantin M; Palatini P; De Martin S; Rosato A; Caruso M; Geroni C; Floreani M
Biochem Pharmacol; 2008 Sep; 76(6):784-95. PubMed ID: 18671948
[TBL] [Abstract][Full Text] [Related]
19. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.
Remmel RP; Crews BC; Kozak KR; Kalgutkar AS; Marnett LJ
Drug Metab Dispos; 2004 Jan; 32(1):113-22. PubMed ID: 14709628
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs.
Andersson SH; Lindgren A; Postlind H
Drug Metab Dispos; 1998 Jun; 26(6):528-35. PubMed ID: 9616187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
